Squarepoint’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.9M | Buy |
533,800
+240,400
| +82% | +$6.29M | 0.01% | 942 |
|
|
2026
Q1 | $8.24M | Sell |
293,400
-281,400
| -49% | -$7.49M | 0.01% | 1183 |
|
|
2025
Q4 | $14.3M | Sell |
574,800
-1,390,900
| -71% | -$35.1M | 0.02% | 902 |
|
|
2025
Q3 | $50.1M | Sell |
1,965,700
-2,879,700
| -59% | -$71.1M | 0.05% | 406 |
|
|
2025
Q2 | $117M | Buy |
4,845,400
+3,899,000
| +412% | +$90.9M | 0.12% | 171 |
|
|
2025
Q1 | $24M | Buy |
946,400
+737,700
| +353% | +$19.3M | 0.03% | 602 |
|
|
2024
Q4 | $5.54M | Sell |
208,700
-407,400
| -66% | -$11.1M | 0.01% | 1555 |
|
|
2024
Q3 | $17.8M | Buy |
616,100
+241,900
| +65% | +$7.06M | 0.03% | 642 |
|
|
2024
Q2 | $10.5M | Sell |
374,200
-917,900
| -71% | -$25.3M | 0.02% | 921 |
|
|
2024
Q1 | $35.9M | Buy |
1,292,100
+945,700
| +273% | +$26.2M | 0.06% | 368 |
|
|
2023
Q4 | $9.97M | Sell |
346,400
-823,600
| -70% | -$24.9M | 0.02% | 956 |
|
|
2023
Q3 | $38.8M | Buy |
1,170,000
+447,200
| +62% | +$15.8M | 0.1% | 232 |
|
|
2023
Q2 | $26.5M | Buy |
722,800
+250,200
| +53% | +$9.74M | 0.08% | 276 |
|
|
2023
Q1 | $19.3M | Sell |
472,600
-219,900
| -32% | -$9.5M | 0.08% | 282 |
|
|
2022
Q4 | $35.5M | Buy |
692,500
+10,500
| +2% | +$503K | 0.14% | 142 |
|
|
2022
Q3 | $29.8M | Sell |
682,000
-89,400
| -12% | -$4.34M | 0.15% | 133 |
|
|
2022
Q2 | $40.4M | Buy |
771,400
+34,300
| +5% | +$1.75M | 0.23% | 77 |
|
|
2022
Q1 | $38.2M | Buy |
737,100
+173,500
| +31% | +$9M | 0.16% | 124 |
|
|
2021
Q4 | $33.3M | Sell |
563,600
-19,700
| -3% | -$976K | 0.09% | 198 |
|
|
2021
Q3 | $25.1M | Sell |
583,300
-52,400
| -8% | -$2.32M | 0.07% | 248 |
|
|
2021
Q2 | $24.9M | Buy |
635,700
+459,700
| +261% | +$17.9M | 0.09% | 197 |
|
|
2021
Q1 | $6.38M | Buy |
176,000
+170,400
| +3,043% | +$6.05M | 0.04% | 528 |
|
|
2020
Q4 | $206K | Sell |
5,600
-3,148
| -36% | -$115K | ﹤0.01% | 2489 |
|
|
2020
Q3 | $305K | Hold |
8,748
| – | – | ﹤0.01% | 1786 |
|
|
2020
Q2 | $271K | Buy |
+8,748
| New | +$297K | ﹤0.01% | 1665 |
|
|
2020
Q1 | – | Sell |
-12,121
| Closed | -$451K | – | 2355 |
|
|
2019
Q4 | $451K | Sell |
12,121
-6,956
| -36% | -$248K | ﹤0.01% | 1826 |
|
|
2019
Q3 | $650K | Buy |
19,077
+4,953
| +35% | +$180K | 0.01% | 1481 |
|
|
2019
Q2 | $580K | Buy |
14,124
+633
| +5% | +$25.1K | 0.01% | 1577 |
|
|
2019
Q1 | $544K | Buy |
+13,491
| New | +$540K | 0.01% | 1446 |
|
Other funds holding PFE
Squarepoint's PFE Position: Q2 2026 in Review
Squarepoint reduced its Pfizer (PFE) stake by 39% in Q2 2026, selling an estimated $55.6M and leaving 3,310,002 shares worth $79.7M. The position accounts for 0.09% of the portfolio, ranked #223.
Squarepoint first reported a position in PFE in Q1 2015 and has held it in 42 quarters since. The position peaked at $262M in Q3 2025. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Squarepoint held 3,310,002 shares of Pfizer worth $79.7M as of Q2 2026.
- Squarepoint sold 2,123,649 Pfizer shares in Q2 2026, an estimated $55.6M.
- Pfizer made up 0.09% of Squarepoint's portfolio in Q2 2026, its #223 holding.
- Squarepoint first reported a position in Pfizer in Q1 2015 and has held it in 42 quarters since.
- Squarepoint's Pfizer position peaked at $262M in Q3 2025.
- 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.